Plasma paraoxonase and arylesterase activities in smokers and smokeless tobacco users as Maraş powder

Inhalation Toxicology

Volumn 26, Issue 4, 2014, Pages 235-239

  Kurtul, Naciye ^a   Söylemez, Saniye ^a,b   Çelik, Mustafa ^a  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

^b MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Mara powder; Nicotiana rustica Linn; Oxidative stress; Paraoxonase; Smokeless tobacco

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; PARAOXON; PHENYLACETIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; MARAS POWDER; OXIDATIVE STRESS; PRIORITY JOURNAL; SMOKELESS TOBACCO; SMOKING;

ADULT; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; HUMANS; MALONDIALDEHYDE; OXIDATIVE STRESS; POWDERS; SMOKING; TOBACCO, SMOKELESS; YOUNG ADULT;

EID: 84896831226     PISSN: 08958378     EISSN: 10917691     Source Type: Journal    
DOI: 10.3109/08958378.2013.878007     Document Type: Article

References (38)

1. Aviram M, Rosenblat M. (2004). Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37:1304-16
2. Aviram M, Rosenblat M, Bisgaier CL, et al. (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-90
3. Bagchi M, Balmoori J, Bagchi D, et al. (1999). Smokeless tobacco, oxidative stress, apoptosis and antioxidants in human oral keratinocytes. Free Radic Bio Med 26:992-1000
4. Barr J, Sharma CS, Sarkar S, et al. (2007). Nicotine induces oxidative stress and activates nuclear transcription factor kappa B in rat mesencephalic cells. Mol Cell Biochem 297:93-9
5. Bazzano LA, He J, Muntner P, et al. (2003). Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138:891-7
6. Buege JA, Aust SD. (1978). Microsomal lipid peroxidation. Meth Enzymol 52:302-10
7. Danesh J, Whincup P, Walker M, et al. (2000). Low grade inflammation and coronary heart disease: Prospective study and updated metaanalyses. Br Med J 321:199-204
8. Durak I, Yalcin S, Cimen MYB, et al. (1999). Effects of smoking on plasma and erythrocyte antioxidant defense systems. J Toxicol Environ Health 56:373-7
9. Durrington PN, Mackness B, Mackness MI. (2001). Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-80
10. Eckerson HW, Wyte CM, La Du BN. (1983). The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35: 1126-38
11. Elkiran ET, Mar N, Aygen B, et al. (2007). Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 15:7-48
12. Frohlich J, Al-Sarraf A. (2013). Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol 22:16-18
13. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. (1988). Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 43:230-8
14. Haj Mouhamed D, Ezzaher A, Araoud M, et al. (2010). Paraoxonase 1 (PON1) activity and lipid parameters in Tunisian smokers. Ann Biol Clin (Paris) 68:143-7
15. Halliwell B. (2006). Oxidative stress and neurodegeneration: Where are we now? J Neurochem 97:1634-58
16. Huen K, Richter R, Furlong C, et al. (2009). Validation of PON1 enzyme activity assays for longitudinal studies. Clin Chim Acta 402:67-74
17. Isik B, Ceylan A, Isik R. (2007). Oxidative stress in smokers and nonsmokers. Inhal Toxicol 9:767-9
18. Katanoda K. (2011). Tobacco or health. In the historical context of epidemiology. Circ J 75:2763-4
19. Kilinc M, Okur E, Kurutas EB, et al. (2004). The effects of Maras powder (smokeless tobacco) on oxidative stress in users. Cell Biochem Funct 22:233-6
20. Kurtul N, Cil MY, Pacaci SD. (2005). Serum total sialic acid levels in smokers and users of smokeless tobacco in form of oral powder (Mara̧s powder). J Biomed Sci 12:559-63
21. Kurtul N, Gökpinar E. (2012). Salivary lipid peroxidation and total sialic acid levels in smokers and smokeless tobacco users as Mara̧s powder. Mediat Inflamm 2012:619293
22. Latha MS, Vijayammal PL, Kurup PA. (1993). Effect of nicotine administration on lipid metabolism in rats. Indian J Med Res 98:44-9
23. Mackness MI, Abbott C, Arrol S, Durrington PN. (1993). The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 294: 829-34
24. Mackness MI, Mackness B, Durrington PN. (2002). Paraoxonase and coronary heart disease. Atheroscler Suppl 3:49-55
25. Nair J, Pakhale SS, Bhide SV. (1989). Carcinogenic tobacco specific nitrosamines in Indian tobacco products. Food Chem Toxicol 27: 751-3
26. Nakayama T, Kodama M, Nagata C. (1984). Generation of hydrogen peroxide and superoxide anion radical from cigarette smoke. Gann 75: 95-8
27. Nielsen F, Mikkelsen BB, Nielsen JB, et al. (1997). Plasma malondialdehyde as a biomarker for oxidative stress: Reference interval and effects of life-style factors. Clin Chem 43:1209-14
28. Nilsson R. (1998). A qualitative and quantitative risk assessment of snuff dipping. Reg Toxicol Pharmacol 28:1-16
29. Nishio E, Watanabe Y. (1997). Cigarette smoke extracts inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 236:289-93
30. Polychronopoulos E, Panagiotakos DB, Polystipioti A. (2005). Diet, lifestyle factors and hypercholesterolemia in elderly men and women from Cyprus. Lipids Health Dis 6:4-17
31. Saitoh F, Noma M, Kawashima N. (1985). The alkaloid contents of sixty nicotine species. Phytochemistry 24:477-80
32. Senti M, Tomas M, Anglada R, et al. (2003). Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: A population based study. Eur J Intern Med 14:178-84
33. Shih DM, Gu L, Xia YR, et al. (1998). Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284-7
34. Tsimikas S, Hall JL. (2012). Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 60:716-21
35. Virani SS, Brautbar A, Davis BC, et al. (2012). Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 125:241-9
36. Weitberg AB, Corvese D. (1999). The effect of epigallocatechin galleate and sarcophytol A on DNA strand breakage induced by tobaccospecific nitrosamines and stimulated human phagocytes. JECCR 18: 433-7
37. Yamaguchi Y, Matsuno S, Kagota S, et al. (2001). Oxidants in cigarette smoke extract modify low-density lipoprotein in the plasma and facilitate atherogenesis in the aorta of Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 156:109-17
38. Yildiz D, Liu YS, Ercal N, Armstrong DW. (1999). Comparison of pure nicotine and smokeless tobacco extract-induced toxicities and oxidative stress. Arch Environ Contam Toxicol 37:434-9